Skip to main content
Premium Trial:

Request an Annual Quote

Svar Life Science, Nimble Therapeutics Form Diagnostics Alliance

NEW YORK — Nimble Therapeutics and Svar Life Science said on Thursday that they have partnered on the development and commercialization of diagnostics for autoimmune diseases.

According to the companies, the alliance will initially focus on rheumatoid arthritis using biomarkers discovered using Nimble's human proteome immunoprofiling technology.

Under the terms of the deal, Nimble will receive an undisclosed upfront payment and stands to receive milestone payments and royalties on product sales. Additional terms were not disclosed.

"Partnering with Svar provides a strong commercial outlet for Nimble's discovery capabilities," Bradley Garcia, vice president of corporate development at Nimble, said in a statement.

Madison, Wisconsin-based Nimble, which was spun out of Roche a year ago, focuses on the discovery of novel peptide drugs using its parallel chemical synthesis platform. Malm, Sweden-based Svar — formerly Euro Diagnostica — develops assay technology for drug development and diagnostic applications.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.